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Abstract
 
Macrophage migration inhibitory factor (MIF) is a potent
proinflammatory mediator that has been shown to potenti-
ate lethal endotoxemia and to play a potentially important
regulatory role in human acute respiratory distress syn-
drome (ARDS). We have investigated whether eosinophils
are an important source of MIF and whether MIF may be
involved in the pathophysiology of asthma. Unstimulated
human circulating eosinophils were found to contain pre-
formed MIF. Stimulation of human eosinophils with phor-
bol myristate acetate in vitro yielded significant release of
MIF protein. For example, eosinophils stimulated with
 
phorbol myristate acetate (100 nM, 8 h, 37
 
8
 
C) released
 
1,539
 
6
 
435 pg/10
 
6
 
 cells of MIF, whereas unstimulated cells
released barely detectable levels (
 
,
 
 142 pg/10
 
6
 
 cells,
 
mean
 
6
 
SEM, 
 
n
 
 
 
5
 
 8). This stimulated release was shown to
be (
 
a
 
) concentration- and time-dependent, (
 
b
 
) partially
blocked by the protein synthesis inhibitor cycloheximide,
and (
 
c
 
) significantly inhibited by the protein kinase C inhib-
itor Ro-31,8220. In addition, we show that the physiological
stimuli C5a and IL-5 also cause significant MIF release.
Furthermore, bronchoalveolar lavage fluid obtained from
asthmatic patients contains significantly elevated levels of
MIF as compared to nonatopic normal volunteers (asth-
matic, 797.5
 
6
 
92 pg/ml; controls, 274
 
6
 
91 pg/ml). These re-
sults highlight the potential importance of MIF in asthma
and other eosinophil-dependent inflammatory disorders. (
 
J.
 
Clin. Invest.
 
 1998. 101:2869–2874.) Key words: granulocyte 
 
•
 
inflammation 
 
• 
 
lung 
 
• 
 
protein kinase C 
 
• 
 
protein synthesis
 
Introduction
 
Macrophage migration inhibitory factor (MIF)
 
1
 
 has been
shown to be an important modulator of the inflammatory re-
sponse (for review, see reference 1). This mediator was origi-
nally described as a T lymphocyte–derived protein that in-
hibited the random migration of guinea pig peritoneal
macrophages (2–4). MIF has subsequently been shown to be a
key modulator of both inflammatory and immune responses
and has been implicated in macrophage activation and in anti-
gen-driven T cell responses (5, 6). MIF is released from im-
mune cells upon glucocorticoid stimulation, and once released
MIF has the unique ability to override glucocorticoid-medi-
ated inhibition of cytokine secretion by both LPS-stimulated
monocytes and antigen-activated T cells (7, 8), and human al-
veolar cells obtained from patients with the acute respiratory
distress syndrome (ARDS) (9). Animal studies have shown
that MIF has the ability to overcome glucocorticoid protection
against lethal endotoxemia (8). It is a mediator in septic shock
and this has been highlighted by the ability of neutralizing anti-
MIF antibodies to protect animals from lethal endotoxemia
(10). Thus, MIF not only exerts proinflammatory effects, but
also counteracts the antiinflammatory action of the glucocorti-
coids. MIF also has recently been shown to be secreted by the
corticotrophic/thyrotrophic cells of the anterior pituitary after
physiological stress or LPS stimulation (10, 11).
In this paper we report that eosinophils, after stimulation
with phorbol myristate acetate (PMA), recombinant human
(rh) C5a, and rhIL-5, are also an important cellular source of
 
MIF. In addition we show that (
 
a
 
) MIF is stored preformed in
significant quantities in eosinophils, (
 
b
 
) eosinophils are capa-
ble of synthesizing MIF, and (
 
c
 
) protein kinase C (PKC) is im-
plicated in the regulation of MIF secretion. Given the involve-
ment of eosinophils in allergic inflammatory disease and the
role MIF plays in counteracting the antiinflammatory action of
the glucocorticoids, we analyzed alveolar fluid derived from
the lungs of stable asthmatic patients and found significantly
elevated MIF levels compared to normal control alveolar fluid.
In this paper we describe the eosinophil as a cellular source for
MIF and highlight the potential importance of MIF as a modu-
lator of the inflammatory response in asthma and other aller-
gic inflammatory diseases.
 
Methods
 
Materials.
 
Sodium citrate was purchased from Phoenix Pharmaceuti-
cals Ltd. (Gloucester, UK). Percoll and dextran were obtained from
Pharmacia Biotechnologies (St. Albans, UK). Iscove’s DME, PBS,
HBSS, and supplements (penicillin and streptomycin) were from Life
Technologies (Paisley, UK). Sterile tissue culture plasticware was
 
Address correspondence to Dr. Seamas C. Donnelly, Respiratory
Medicine Unit, Rayne Laboratory, University of Edinburgh, Medical
School, Teviot Place, Edinburgh, EH8 9AG United Kingdom. Phone:
44-131-651-1324; FAX: 44-131-650-4384; E-mail: sdon@srv1.med.
ed.ac.uk
 
Received for publication 16 December 1997 and accepted in re-
vised form 2 April 1998.
 
1. 
 
Abbreviations used in this paper:
 
 ARDS, acute respiratory distress
syndrome; BAL, bronchoalveolar lavage; MIF, macrophage migra-
tion inhibitory factor; PKC, protein kinase C; PMA, phorbol myri-
state acetate; rh, recombinant human.
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purchased from CorningCostar (High Wycombe, UK) and Falcon
(Baker Scientific, Runcorn, UK). PMA, rhC5a, and cycloheximide
were purchased from Sigma Chemical Co. Ltd. (Poole, UK). Dyna-
beads (M-450) were purchased from Dynal (Merseyside, UK). Ro-
31,8220 was purchased from Calbiochem–Novabiochem Ltd. (Not-
tingham, UK) and rhIL-5 from R&D (Abingdon, UK).
 
Eosinophil isolation and culture.
 
Eosinophils were isolated by a
modification of a previously described method (12, 13). Briefly, eosin-
ophils derived from the peripheral blood of normal donors were iso-
lated by dextran sedimentation followed by centrifugation through
discontinuous plasma–Percoll gradients. Granulocytes were taken
from the 70/81% layer and the eosinophils were purified from con-
taminating neutrophils by an immunomagnetic separation step, using
sheep anti–mouse IgG Dynabeads coated with the murine an-
tineutrophil antibody 3G8 (anti-CD16; a gift from Dr. J. Unkeless,
Mount Sinai Medical School, New York). Cells were mixed with
washed 3G8 Dynabeads at a bead/neutrophil ratio of 3:1 on a rotary
mixer at 4
 
8
 
C for 20 min, and beads with bound neutrophils were re-
moved magnetically by stationary contact (3 min) with a magnet
(Magnetic Particle Concentrator MPC-1; Dynal). This procedure was
repeated once to yield an eosinophil population of 
 
.
 
 98% purity and
 
.
 
 99% viability. After purification, cells were washed sequentially in
HBSS without calcium or magnesium and HBSS with calcium and
magnesium before resuspending in Iscove’s DME with 2% autolo-
gous serum. Eosinophils (10
 
6
 
/ml) were cultured in Iscove’s DME with
2% autologous serum at 37
 
8
 
C in a 5% CO
 
2
 
 atmosphere.
 
MIF ELISA.
 
Immunoreactive MIF in collected cell supernatants,
lysates, and patient samples were quantitated via standard ELISA as
published previously (9). Plates were coated with an anti–human MIF
mAb and were blocked and incubated using standard methods. Rab-
bit polyclonal anti-MIF sera were used as secondary antibodies, fol-
lowed by goat anti–rabbit IgG conjugated to alkaline phosphatase
substrate (para-NPP). MIF levels were determined by extrapolating
from a quadratic standard curve using purified, human rMIF (range
0–12 ng/ml) (14). The sensitivity of this ELISA was 
 
$ 
 
150 pg/ml.
 
Patient details.
 
Asthmatic patients attending the Respiratory
Outpatients Department at the Western General Hospital, (Edin-
burgh, UK) were considered eligible for study enrollment. Our nor-
mal nonsmoking control group was paramedical staff within the
Western General Hospital. Informed written consent was obtained
from volunteers or asthmatic patients before bronchoscopy. Asth-
matic patients were eligible for enrollment if they (
 
a
 
) were 
 
.
 
 18 yr of
age, (
 
b
 
) had not been prescribed oral corticosteroid medication for at
least 3 mo before enrollment, (
 
c
 
) had a forced expiratory volume-1
(FEV1) 
 
.
 
 1 liter and (
 
d
 
) had oxygen saturation values on air of 
 
.
 
 90%
before the procedure. This study was approved by the Lothian Health
Board Ethics Committee.
 
Bronchoalveolar lavage (BAL) procedure.
 
BAL sampling was
performed as described previously (15). Briefly, asthmatic patients
were prescribed nebulized salbutamol (2.5 mg) before bronchoscopy.
Premedication consisted of phenoperidine (up to 1 mg) and mida-
zolam (up to 3 mg) intravenously. A fiber-optic bronchoscope was in-
troduced intranasally and passed through the vocal cords into the
lungs. The distal end of the bronchoscope was wedged into either the
lingula or right middle lobe. Eight 30-ml aliquots of 0.9% NaCl solu-
tion were instilled and gently aspirated immediately. All bronchos-
copy procedures were performed by the same bronchoscopist (A.P.
Greening). On average, 76% of instilled NaCl solution was recov-
ered. Recovered fluid and cells were stored at 4
 
8
 
C until processed.
All samples were processed within 1 h of collection.
For collected samples, processing initially entailed straining the
lavage fluid through sterile gauze to remove mucous. The strained
fluid was then centrifuged at 400 
 
g
 
 at 4
 
8
 
C for 10 min to recover cells.
Total cell counts were performed using a hemocytometer. Aliquots of
cells were pelleted onto glass slides using a cytospin 2 (Shandon Sci-
entific, Cheshire, UK) and then stained with Diff-Quick (Merz–Dade
AG, Dudingen, Switzerland), a modified Wright–Giemsa stain. Dif-
ferential counts were determined by counting 500 cells under oil im-
Figure 1. PMA stimulates eosinophils to secrete MIF. Human eo-
sinophils (106/ml in Iscove’s DME containing 2% autologous serum) 
were cultured with (A) PMA (100 nM) for 8 h (n 5 8); (B) PMA (1, 
10, and 100 nM PMA for 8 h) (n 5 4); and (C) PMA (100 nM) for 1, 4, 
and 8 h (n 5 3). The cells were centrifuged (800 g, 2 min) and the su-
pernatant assessed for the presence of MIF by specific ELISA. Re-
sults are expressed as the amount of MIF (pg/ml) released mean6 
SEM where significant difference above control values is represented 
by *P , 0.05.
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mersion (
 
3
 
100). The lavage fluid supernatant was respun at 1,000 
 
g
 
for 10 min at 4
 
8
 
C to remove cellular debris and stored at 
 
2
 
70
 
8
 
C until
analyzed at a later date. MIF was assayed in unconcentrated, neat
BAL samples and MIF results are expressed per milliliter of collected
BAL fluid.
 
Statistical analysis.
 
The results are expressed as mean
 
6
 
SEM. Sta-
tistical analysis was performed by the Student’s 
 
t
 
 test or by one-way
ANOVA followed by the Newmans–Keuls post-test. Analysis of MIF
levels in BAL fluid was performed using the Spearman rank correla-
tion. Differences were considered significant when 
 
P
 
 
 
,
 
 0.05. Calcula-
tions were performed using the statistical software package Statview
(Abacus Concepts, Berkeley, CA).
 
Results
 
MIF secretion from PMA-stimulated eosinophils.
 
Eosinophils
were found to be efficient secretors of MIF after PMA stimu-
lation. In 8-h cultures, human blood–derived eosinophils re-
leased a mean value of 1539
 
6
 
435 pg/ml MIF per million cells
after PMA stimulation (100 nM) (Fig. 1 
 
A
 
) (
 
P
 
 
 
5
 
 0.0008). This
secretion was concentration-dependent with 1, 10 and 100 nM
PMA inducing 803
 
6
 
230, 1,084
 
6
 
161, and 1,718
 
6
 
48 pg/ml MIF,
respectively, in collected 8-h supernatants (Fig. 1 
 
B
 
). The time
course of MIF secretion after stimulation (Fig. 1 
 
C
 
) revealed
mean MIF release at 1, 4, and 8 h of 1,706
 
6
 
1,259, 1,309
 
6
 
430,
and 1,886
 
6
 
1,013 pg/ml, respectively.
 
MIF is stored preformed in eosinophils. 
 
The observation
that MIF was found in eosinophil supernatants 1 h after PMA
stimulation suggested that significant MIF resides preformed
in eosinophils. Analysis of unstimulated eosinophil lysates and
supernatants revealed a mean level of MIF of 111
 
6
 
66.2 and
2,883
 
6
 
706 pg/ml in control supernatant and lysate samples, re-
spectively. 8 h after PMA stimulation, supernatant and lysate
values were 1,793
 
6
 
610 and 2057
 
6
 
807 pg/ml, respectively (Fig.
2 
 
A
 
). Pretreatment with cycloheximide (1 
 
m
 
M) resulted in a re-
duction in MIF secretion after PMA stimulation by 53% com-
pared to untreated stimulated cells (Fig. 2 
 
B
 
).
 
Influence of PKC inhibitors on MIF secretion. 
 
Preincuba-
tion of eosinophils with Ro-31,8220 (1 
 
m
 
M), a PKC inhibitor,
resulted in an attenuation of PMA-induced MIF secretion by
72% in 8-h supernatants. PMA secretion was reduced from a
mean of 2,663
 
6
 
831 to 744
 
6
 
254 pg/ml after preincubation with
the PKC inhibitor (control, 86
 
6
 
46 pg/ml) (Fig 3).
 
IL-5 and C5a induce eosinophil MIF secretion.
 
In relation
to the pathophysiology of inflammatory lung disease and
asthma, we investigated whether mediators known to be impli-
cated in these diseases (e.g., IL-5 and C5a) could induce MIF
secretion from eosinophils. Incubation of human eosinophils
with rhIL-5 (100 ng/ml) resulted in a mean MIF level of 1,169
pg/ml in collected supernatants. Preincubation with rhC5a
(100 nM) resulted in a mean level of 1,167 pg/ml (Table I).
 
MIF alveolar levels in asthma.
 
Nonatopic normal volun-
teers and stable asthmatic patients were bronchoscoped and
BAL samples obtained. Significantly elevated alveolar MIF
levels were found in asthmatic patients compared to controls
(
 
P
 
 
 
,
 
 0.005) (asthmatic, 797.5
 
6
 
92 pg/ml; controls, 274
 
6
 
91 pg/
ml) (Fig. 3). The mean number of total BAL cells obtained
 
Figure 2.
 
MIF is both stored and newly synthesized and its secretion 
is controlled by PKC. Eosinophils (10
 
6
 
/ml in Iscove’s DME contain-
ing 2% autologous serum) were cultured with (
 
A
 
) buffer or PMA 
(100 nM) for 8 h and MIF levels in cell lysates (
 
L
 
) and supernatants 
(
 
S
 
) were determined (
 
n
 
 
 
5
 
 3); (
 
B
 
) PMA (100 nM) for 8 h in the ab-
sence and presence of cycloheximide (
 
CXM
 
) (1 
 
m
 
M; 
 
n
 
 
 
5
 
 4; 
 
C
 
, con-
trol) and (
 
C
 
) PMA (100 nM) for 8 h in the absence or presence of
Ro-31, 8220 (
 
n
 
 
 
5
 
 3). The cells were centrifuged (800 
 
g, 2 min) and the 
supernatant and/or cell lysate assessed for the presence of MIF by 
specific ELISA. Results are expressed as the amount of MIF (pg/ml) 
mean6SEM where significant difference above control values are 
represented by *P , 0.05 and differences between PMA-stimulated 
cells and CXH- or Ro-31,8220-treated cells are represented by #P , 
0.05.
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was 11.37 3 106. No significant correlation was obtained be-
tween alveolar MIF levels and total BAL cell number (P 5
0.42), total number of eosinophils (P 5 0.79), macrophages
(P 5 0.60), lymphocytes (P 5 0.54), or neutrophils (P 5 0.42).
Discussion
MIF was originally described over 30 yr ago as a soluble activ-
ity produced by activated T cells that inhibited the random mi-
gration of cultured guinea pig macrophages (3, 4). Recently,
MIF has been rediscovered to be a critical regulatory mediator
whose secretion is induced by glucocorticoids and that has the
capacity, in its own right, to counterregulate the inhibitory ef-
fects of glucocorticoids in the immune system (4). This dual
role of maximizing inflammatory activity by being directly
proinflammatory, and by indirectly inhibiting maximal antiin-
flammatory glucocorticoid activity, led us to investigate the
potential role of MIF in pulmonary inflammatory disease.
ARDS represents a catastrophic form of acute lung injury that
arises as a consequence of overwhelming inflammation. We
have recently described a potential regulatory role for MIF
in ARDS (9). In this study, we showed evidence within lung
tissue and within the alveolar airspace of excessive MIF pro-
duction. In addition MIF was shown to both augment proin-
flammatory cytokine production and override the antiinflam-
matory effects of glucocorticoids on ex vivo ARDS alveolar
cells.
This work led us to consider the potential role of MIF in an
allergic inflammatory disease, namely asthma. The eosinophil
has been implicated as a key cell type in the pathogenesis of al-
lergic inflammatory diseases such as bronchial asthma, allergic
rhinitis, and atopic dermatitis (16, 17). Eosinophils are re-
cruited to inflammatory foci by the concerted effects of spe-
cific chemoattractants, adhesion molecules, and extracellular
matrix proteins. Once recruited, eosinophils, if further ex-
posed to inflammatory stimuli, become activated and can un-
dergo a variety of functional responses including degranula-
tion, liberation of reactive oxygen intermediates (ROI), and
synthesis and release of inflammatory mediators and cyto-
kines. Secreted products such as eosinophil cationic protein,
major basic protein, eosinophil protein X, and eosinophil per-
oxidase, as well as reactive oxygen intermediates, assist in de-
struction of invading organisms and contribute to tissue dam-
age associated with allergic diseases and asthma. For example,
in asthma, elevated levels of eosinophil-derived products are
found in the BAL fluid and correlate positively with the severity
of the disease. Furthermore, when certain eosinophil-derived
products are administered into the lungs of animals, bronchial
hyperresponsiveness and lung damage can occur, further im-
plicating the eosinophil as detrimental and contributing to the
pathogenesis of asthma (for review, see references 16 and 18).
Clinically, administration of glucocorticoids has been used suc-
cessfully as a way of reducing inflammatory cell–induced tissue
damage and amelioration of eosinophilic diseases. Although
the mechanism of action of glucocorticoids in such diseases is
unknown, in patients with hypereosinophilia there is a marked
reduction in the number of circulating eosinophils, an inhibi-
tion of eosinophil recruitment to inflammatory sites, a damp-
ening of eosinophil responsiveness, and an increase in eosino-
phil apoptosis with subsequent removal by macrophages (13,
19–22). Thus, identifying and characterizing eosinophil-derived
mediators and defining their biological effects will help to elu-
cidate the cellular mechanisms involved in eosinophilic dis-
eases and have far-reaching implications in developing thera-
peutic targets.
In this study we report that eosinophils are an important
source of MIF, a cytokine capable of counteracting the effects
of glucocorticoids. We show that PMA-induced MIF secretion
occurs rapidly, with significant extracellular MIF being found
within 1 h after stimulation. Even at 8 h, despite pretreatment
with cycloheximide, MIF levels attained 47% of untreated
Figure 3. MIF levels are elevated in BAL fluid obtained from stable 
asthmatic patients compared to levels in alveolar fluid obtained from 
normal controls. BAL samples were obtained from normal controls 
(n 5 10) and asthmatic patients (n 5 32) as described in Methods and 
MIF was determined by specific ELISA. Results are expressed as the 
amount of MIF (pg/ml) obtained in each individual BAL sample. The 
mean6SEM values obtained from asthmatic patients were 797.5692 
and 274691 pg/ml from normal controls (P , 0.005).
Table I. Physiological Stimuli C5a and IL-5 Induce
MIF Secretion
Exp. 1 Exp. 2
Control (unstimulated) 439 544
IL-5 (100 ng/ml) 843 1495
C5a (100 nM) 913 1420
Human eosinophils (106/ml) in Iscove’s DME (containing 2% autologous
serum) were cultured alone (control), with rhC5a (100 nM), or with
rhIL-5 (100 ng/ml) for 8 h. The cells were centrifuged (800 g, 2 min) and
the supernatant assessed for the presence of MIF by specific ELISA
(each treatment assayed in triplicate).
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PMA positive control. This suggests a possible role for MIF in
both early and later eosinophil-induced inflammation in
asthma and other allergic inflammatory diseases.
PMA is known to directly interact with PKC and therefore
bypass classical receptor/G protein effects. We investigated
whether the concentration- and time-dependent PMA-induced
MIF release was also mediated by this pathway. Using the spe-
cific PKC inhibitor Ro-31,8220 we show that the PMA-stimu-
lated response was almost totally blocked by this inhibitor im-
plying that PKC regulates PMA-stimulated release. We were
also interested in determining whether other significant eosi-
nophil activators that have been implicated in asthma disease
pathogenesis (23, 24) stimulated MIF secretion from human
eosinophils. Both IL-5 and C5a enhanced MIF secretion from
these cells. The levels of MIF secretion after stimulation by
rhC5a and rhIL-5 were z 70% of levels obtained by stimula-
tion with PMA.
With our identification of the eosinophil as an additional
circulating cellular source for MIF, and the well recognized
role MIF plays in counteracting the antiinflammatory actions
of glucocorticoids, we wished to investigate whether elevated
intraalveolar MIF levels exist in asthmatic patients. In BAL
samples obtained from stable asthmatic patients significantly
elevated intraalveolar MIF levels were detected compared to
nonsmoking controls (P , 0.005). These findings support the
role for MIF in contributing to sustaining the pulmonary in-
flammatory response in asthma. There was no direct correla-
tion between MIF levels and total eosinophil numbers in BAL
samples. This does not necessarily mean that the MIF we de-
tected was not derived from eosinophils, since a direct correla-
tion between these parameters would occur only if the whole
eosinophil population uniformly secreted MIF throughout
their tissue life-span in asthmatic lungs, and many other factors
are likely to impinge on the kinetics of eosinophil MIF secre-
tion in situ. Nevertheless it is important to recognize that other
cells, including macrophages and lymphocytes (3–5), may also
contribute to the levels of MIF that we detected in BAL fluid
from asthmatics.
To date MIF has been implicated in immune diseases of the
kidney and in ARDS (9, 25, 26). In ARDS we have found the
median intraalveolar MIF levels in a severe form of acute in-
flammatory lung injury, namely ARDS, to be 1,190 pg/ml (9).
The median level found in our stable asthmatic population was
772.5 pg/ml. One could envisage that in acute inflammatory
asthmatic exacerbations requiring hospital admission, intraal-
veolar MIF levels would be elevated still further. This raises
the possibilities of MIF as a significant contributor to sustain-
ing the heightened inflammatory response, and of anti-MIF as
a novel therapeutic strategy in asthma and other allergic in-
flammatory diseases. Further work is required to address these
important questions.
In asthma, it is possible that in addition to MIF’s potent
proinflammatory activity, its ability to override the antiinflam-
matory activity of glucocorticoids may also significantly con-
tribute towards an exaggerated pulmonary inflammatory re-
sponse in asthma. Glucocorticoid therapy represents the gold
standard antiinflammatory treatment in asthma. However, it is
well recognized that a proportion of patients fail to respond
to prescribed glucocorticoids and these patients have been
termed steroid-resistant asthmatics (27, 28). Today, the prob-
lem of a blunted clinical response or resistance to prescribed
glucocorticoids is well recognized, particularly in hospital-
based asthma practice. MIF could potentially also play a role
in this blunted response to steroids. Our findings of significant
intrapulmonary MIF evident within the alveolar airspaces of
stable asthmatics combined with our knowledge of the ability
of MIF to override, in a concentration-dependent manner, glu-
cocorticoid antiinflammatory function on ex vivo inflamma-
tory cells suggest that MIF may play a role in inhibiting maxi-
mal endogenous or exogenous steroid activity in inflammatory
diseases such as asthma. This finding is potentially of thera-
peutic importance, as an anti-MIF strategy would not only be
antiinflammatory in its own right, but would also act by remov-
ing the potential inhibitory role of MIF on glucocorticoid func-
tion. This could serve to restore maximal antiinflammatory
steroid activity, and reset the balance within the pulmonary in-
flammatory response away from excessive inflammation, air-
way constriction, and tissue damage.
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